Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05313165 · ClinicalTrials.gov registry record · NA
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
A NA study of Peripheral Arterial Disease and Critical Limb Ischemia, sponsored by LimFlow.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT05313165 is a NA study of Peripheral Arterial Disease and Critical Limb Ischemia that is actively recruiting participants, run by LimFlow. The registered enrollment target is 100 participants, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT05313165, a NA study of Peripheral Arterial Disease and Critical Limb Ischemia, is actively recruiting participants, sponsored by LimFlow.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
Conditions Studied
Interventions
- DEVICE LimFlow Stent Graft System
Study Locations (20)
California
- University of California, San Diego Health - La Jolla
- Stanford University School of Medicine - Palo Alto
- UCSF - San Francisco
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - Torrance
Florida
- The Cardiac and Vascular Institute - Gainesville
- University of Florida - Gainesville
- Tallahassee Research Institute - Tallahassee
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Medical Center - Boston
- UMass Chan Medical School - Worcester
New York
- Northwell Health Long Island Jewish Medical Center - Lake Success
- NYU Langone Health - New York
- Mount Sinai - New York
New Jersey
- Vascular Institute of Atlantic Medical Imaging - Pomona
- Holy Name Medical Center - Teaneck
Connecticut
- Yale University - New Haven
Illinois
- Rush University Medical Center - Chicago
Missouri
- Washington University / Barnes Jewish - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05313165
The ClinicalTrials.gov registry entry for NCT05313165 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The listed sponsor is LimFlow, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which LimFlow Stent Graft System is the first listed.
NCT05313165 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05313165 about?
NCT05313165 is a clinical study titled "PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia". A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.
What is the current status of trial NCT05313165?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-12-22. Estimated completion is 2027-05-01.
What conditions does trial NCT05313165 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Critical Limb Ischemia, Chronic Limb-Threatening Ischemia.
What interventions are being tested in trial NCT05313165?
The interventions under investigation include: LimFlow Stent Graft System (DEVICE).
Who is sponsoring clinical trial NCT05313165?
This trial is sponsored by LimFlow, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05313165 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.